FTC Chair Plans to Explore All Options in PBM Investigations
The chair of the US Federal Trade Commission (FTC), Lina Khan, has pledged to use all the tools at her disposal to investigate the practices of pharmacy benefit managers (PBMs), who have recently faced increasing scrutiny. This is due to allegations of anti-competition and price fixing. A formal investigation by the agency was announced this summer.
Court Rules Against FTC in Illumina Antitrust Case
A US judge has ruled against the Federal Trade Commission (FTC) in its antitrust case against Illumina. The agency had sued the company for its $7 Billion buyout of Grail, a biotech that tests for cancer using blood samples. Illumina is a leader in DNA sequencers used by Grail and its competitors, which the FTC claimed would make the deal anti-competitive.
Congressional Democrats Seek DOJ and FTC Investigation into Blood Thinner Price Hikes
Johnson & Johnson and Bristol Meyers Squib are facing increasing scrutiny from members of the US Congress after allegations of [...]
FTC Begins Probe into Anticompetitive Practices of Leading PBMs
The US Federal Trade Commission has launched its investigation into the practices of the largest pharmacy benefit managers (PBMs) and [...]
US Senate Introduces Bill to Give FTC More Power Over PBMs
A new bill in the US Senate would, if enacted, give the Federal Trade Commission (FTC) more power to control [...]
RWJ Foundation Study Reveals Unhealthiest County US State
Health disparities in the US exist on the state and county level, with several rural areas experiencing significantly higher levels [...]
CSL’s Acquisition of Vifor Pharma Hits Antitrust Snags
The multinational biotech CSL’s planned purchase of Vifor Pharma has been put on pause due to antitrust concerns. The $11.7 [...]
FTC Faces Pressure from Pharmacies to Act on High Drug Costs
As the cost of prescription drugs continues to rise, the Federal Trade Commission (FTC) is under increased pressure from independent [...]
Pricing and Competition Regulatory Attempts Chill Mergers and Acquisitions in Pharma
As nations and their regulatory bodies dial up the pressure on drug pricing, pharmaceutical companies have become uneasy regarding mergers [...]
